FDA Panel Votes to Add Peptides to Compounding List
The FDA's Pharmacy Compounding Advisory Committee voted to add peptides to the list of substances compounding pharmacies can make. The decision was made despite concerns from agency scientists over the lack of demonstrated benefits.
The Food and Drug Administration's committee on compounded drugs voted on Thursday to add peptides to the list of substances compounding pharmacies can make. This decision was made after the committee heard public comments and saw presentations by agency staffers concerning the peptides BPC-157, KPV, TB-500, and MOTS-C. The FDA's Pharmacy Compounding Advisory Committee made this decision despite opposition from agency scientists who raised concerns over the lack of demonstrated benefits. The peptides in question have been considered for addition to the permitted compounding list. Agency scientists presented their findings, which included concerns about the peptides. The committee's vote reflects a decision to move forward with adding these substances to the list. The FDA will now consider the committee's recommendation. The decision could impact how compounding pharmacies operate and what substances they are allowed to make. The FDA's consideration of the peptides is part of its ongoing effort to regulate compounding pharmacies. The agency has been working to ensure that these pharmacies operate safely and effectively. The committee's vote is one step in this process. The FDA will continue to evaluate the use of peptides in compounding pharmacies and make decisions based on the available evidence.
Go Deeper
What are peptides and how are they used?
Peptides are short chains of amino acids and are used in a variety of medical applications. They can be used to treat a range of conditions, including injuries and diseases. The peptides in question, BPC-157, KPV, TB-500, and MOTS-C, have been considered for their potential therapeutic benefits.
What is the FDA's role in regulating compounding pharmacies?
The FDA is responsible for regulating compounding pharmacies to ensure they operate safely and effectively. This includes evaluating the substances they use and making decisions about what substances are allowed. The FDA's goal is to protect public health by ensuring that compounding pharmacies produce high-quality products.
Why did agency scientists oppose the addition of peptides to the compounding list?
Agency scientists opposed the addition of peptides to the compounding list due to concerns over the lack of demonstrated benefits. They presented their findings to the committee, highlighting the need for more evidence on the safety and effectiveness of these substances.
What is the next step in the process?
The FDA will now consider the committee's recommendation to add peptides to the permitted compounding list. The agency will evaluate the available evidence and make a decision based on this evidence. This decision will impact how compounding pharmacies operate and what substances they are allowed to make.
How will this decision impact compounding pharmacies?
The decision to add peptides to the permitted compounding list could impact how compounding pharmacies operate. It may allow them to produce a wider range of products, which could be beneficial for patients. However, it also raises concerns about the safety and effectiveness of these substances, which the FDA will need to carefully evaluate.
More health
healthWomen discuss the luteal phase on social media
The luteal phase is a topic of increasing discussion among women on social media. Women are sharing their experiences and symptoms associated with thi
Aug 3
healthUK Clinic Takes Steps to Boost Falling Child Immunization Rates
A clinic in west Yorkshire is working to increase child immunization rates as they fall across the UK. The clinic's efforts come as health officials l
Aug 3
health50+Two deaths reported in Michigan cyclospora outbreak
Two people in Michigan have died in connection with the multistate cyclosporiasis outbreak. The individuals who died had significant underlying health
Aug 3